The Severe Asthma Checklist is a guide to identifying patients with severe asthma among adults and adolescents with asthma that is not well controlled despite treatment.
This resource was prepared in consultation with Dr Ian Almond, general practitioner, and Professor Peter Wark, adult respiratory physician.
Funded by an independent grant from AstraZeneca Australia. AstraZeneca has not been involved in the development, review or editing of this publication.
Although all care has been taken, this resource is a general guide only, which is not a substitute for assessment of appropriate courses of treatment on a case-by-case basis. The National Asthma Council Australia expressly disclaims all responsibility (including for negligence) for any loss, damage, or personal injury resulting from reliance on the information contained herein.
Four monoclonal antibody therapies (benralizumab, mepolizumab, dupilumab and omalizumab) are available in Australia for the treatment of severe asthma in patients whose asthma is uncontrolled despite optimised standard treatment.
Latest evidence on the prevalence and impact of incorrect technique, plus checklists for using each inhaler correctly